A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Trial Details

NCT ID

NCT06996782

Phase

PHASE1 / PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Non-Small Cell (NSCLC) Lung Cancer

Interventions

Rilvegostomig
Cisplatin
Carboplatin
Pemetrexed
Paclitaxel
Nab-paclitaxel

Locations (sample)

Phoenix, Arizona, United States|33.44838,-112.07404
Santa Rosa, California, United States|38.44047,-122.71443
Jacksonville, Florida, United States|30.33218,-81.65565
Baltimore, Maryland, United States|39.29038,-76.61219
Detroit, Michigan, United States|42.33143,-83.04575

Key Eligibility Criteria

Participants with confirmed squamous or non-squamous NSCLC with a current Stage IV mNSCLC.
Provision of acceptable archival tumour tissue (or fresh tumour tissue biopsy if archival tumour tissue is not available and if clinically feasible…
Measurable disease as defined by at least one lesion that can be accurately measured at baseline as ≥ 10 mm at the longest diameter.
Minimum life expectancy of 12 weeks in the opinion of the investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →